MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
40.72
-0.09 (-0.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close40.81
Open40.72
Bid40.20 x 1000
Ask42.19 x 200
Day's Range40.43 - 40.99
52 Week Range29.39 - 47.82
Volume3,087,468
Avg. Volume4,775,407
Market Cap20.962B
Beta1.33
PE Ratio (TTM)31.32
EPS (TTM)1.30
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est49.95
Trade prices are not sourced from all markets
  • MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade
    Yahoo Finance Video4 days ago

    MARKETS: Wall Street's biggest fear is a trade war and FAANG+BAT is still the most crowded trade

    Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.

  • MARKETS: Here's the line in the equity sand bulls must defend
    Yahoo Finance Video8 days ago

    MARKETS: Here's the line in the equity sand bulls must defend

    Yahoo Finance's Jared Blikre joins Seana Smith from the New York Stock Exchange to discuss the latest market moves.

  • Mylan CEO on rising drugs prices in the U.S.
    Yahoo Finance Video9 days ago

    Mylan CEO on rising drugs prices in the U.S.

    Drug prices are a top issue for Americans, and President Trump pledged to cut high drug costs throughout the beginning of his presidency. Heather Bresch, CEO of Mylan, talks with Yahoo Finance's Seana Smith and Andy Serwer.

  • Reuters19 hours ago

    Mylan cuts 15 pct of workforce at West Virginia plant

    Generic drugmaker Mylan NV on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown, West Virginia. The company, which had faced intense criticism and political scrutiny over price hikes for its life-saving EpiPen emergency allergy treatment, said the Morgantown plant "needed to be rightsized to be less complex" for continued operations. The layoffs involved more than 400 employees represented by a United Steel Workers local union, reported WAJR, a Morgantown radio station.

  • Reuters3 days ago

    Canada seeks U.S. help to solve EpiPen shortage

    Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.

  • Investopedia4 days ago

    7 Stock Picks With Giant Upside: Goldman

    Green Pastures: DISH, AbbVie, Hasbro and other stocks are poised to flourish

  • Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out
    InvestorPlace4 days ago

    Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out

    At first glance, Pfizer Inc. (NYSE:PFE) appears a worthwhile contrarian trade. Additionally, the overall markets have been soft, allowing shrewd investors to pick up PFE stock at a more attractive valuation. As a result, many analysts are questioning whether Pfizer stock, at its present cost, is worth the risk.

  • EpiPen shortages seen in Canada, UK but U.S. supply intact
    Reuters7 days ago

    EpiPen shortages seen in Canada, UK but U.S. supply intact

    By Bill Berkrot NEW YORK (Reuters) - Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday. EpiPens deliver potentially lifesaving doses of the generic drug epinephrine, via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction. Currently there is no shortage in the U.S.," said Steve Danehy, a spokesman for Pfizer Inc , which produces the global supply of EpiPens for Mylan out of a single facility near St. Louis, Missouri.

  • Reuters8 days ago

    EpiPen shortages seen in Canada, UK but U.S. supply intact

    Mylan N.V.'s emergency allergy antidote EpiPen is in short supply in Canada and Britain, but remains available in the United States, the treatment's manufacturer said on Friday. EpiPens deliver potentially lifesaving doses of the generic drug epinephrine, via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction. Currently there is no shortage in the U.S.," said Steve Danehy, a spokesman for Pfizer Inc , which produces the global supply of EpiPens for Mylan out of a single facility near St. Louis, Missouri.

  • Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
    Investor's Business Daily8 days ago

    Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz

    Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.

  • Mylan seeks deal for German Merck's consumer products unit: sources
    Reuters8 days ago

    Mylan seeks deal for German Merck's consumer products unit: sources

    FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said. "Although it's Mylan's policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue," Mylan said in a statement on Friday. A Mylan spokeswoman declined to offer details on what in the Reuters story was inaccurate.

  • Mylan seeks deal for German Merck's consumer products unit - sources
    Reuters8 days ago

    Mylan seeks deal for German Merck's consumer products unit - sources

    FRANKFURT/NEW YORK (Reuters) - Generic drug maker Mylan NV is in advanced discussions to acquire Merck KGaA's consumer health business after other bidders failed to meet the German company's price expectations, people familiar with the matter said. "Although it's Mylan's policy to not comment on rumours or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue," Mylan said in a statement on Friday. A Mylan spokeswoman declined to offer details on what in the Reuters story was inaccurate.

  • Merck KGaA Consumer Unit Is a Deal Too Far for Mylan
    Bloomberg8 days ago

    Merck KGaA Consumer Unit Is a Deal Too Far for Mylan

    The drugmaker isn't in a position to take on a lot more debt.

  • ACCESSWIRE8 days ago

    Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics for Commercializing Biosimilar to Humira(R) (adalimumab)

    Stock Monitor: SteadyMed Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on Mylan N.V. (NASDAQ: MYL ). If you want access ...

  • Reuters8 days ago

    Mylan seeks deal for German Merck’s consumer products unit -sources

    Generic drug maker Mylan is in advanced discussions to acquire Merck KGaA’s consumer health unit after other bidders failed to meet the German company’s price expectations, people familiar with the matter ...

  • Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
    Zacks9 days ago

    Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

    Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

  • Analyst Urges Investors To Buy This Drugmaker's Dip — And They Do
    Investor's Business Daily9 days ago

    Analyst Urges Investors To Buy This Drugmaker's Dip — And They Do

    Mylan shares rebounded Thursday following worries that first-quarter sales would lag based on tough comparisons for allergy drug EpiPen.

  • TheStreet.com9 days ago

    Mylan's Stock Gets Bump After Investor Day

    Following Wednesday's event, Leerink analyst Ami Fadia said she is 'incrementally more positive' on the drugmaker's pipeline and diversified business model and moved her rating to outperform.

  • Benzinga9 days ago

    Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms

    Mylan NV (NASDAQ: MYL )’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to ...

  • Stocks rally as investors digest Trump's latest Syria tweet
    Yahoo Finance9 days ago

    Stocks rally as investors digest Trump's latest Syria tweet

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

  • MarketWatch9 days ago

    Mylan's stock rallies after investor day leads to upgrade at Leerink

    Mylan N.V.'s stock rallied 1.0% in morning trade Thursday, after the generic drugmaker was upgraded at Leerink Partners, which cited a more positive pipeline outlook. Analyst Ami Fadia raised her rating ...

  • Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
    Zacks10 days ago

    Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

    Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

  • TheStreet.com10 days ago

    Mylan Spotlights Diversification at Investor Day

    The drug company generates about 60% of revenue outside the U.S.

  • Investor Day Highlights Durability of Mylan's Global Platform
    PR Newswire10 days ago

    Investor Day Highlights Durability of Mylan's Global Platform

    HERTFORDSHIRE, England and PITTSBURGH, April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand access to medicine, commitment to complex scientific programs and commercial diversification, and significant financial flexibility. Mylan CEO Heather Bresch commented: "For nearly 60 years, Mylan has remained true to its core purpose of providing access to medicine. Today, for example, we estimate that 75% of the cash flows that Mylan generates are stable and durable.

  • Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication
    PR Newswire10 days ago

    Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication

    HERTFORDSHIRE, England and PITTSBURGH, April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced that it has acquired global development and marketing rights from Prayog Labs LLC to bring to market a fast-acting Meloxicam as a proposed non-narcotic analgesic. This novel delivery has the potential to provide a non-addictive treatment option for acute pain that patients may experience, for example, during dentistry procedures, post-surgery and with orthopedic defects. Meloxicam also is proposed to treat chronic pain.